Catalyst Pharmaceutical CPRX Payment Of Liabilities Arising From Asset Acquisition
Payment Of Liabilities Arising From Asset Acquisition at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's payment of liabilities arising from asset acquisition.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's payment of liabilities arising from asset acquisition?
- Catalyst Pharmaceutical (CPRX) reported payment of liabilities arising from asset acquisition of $1.3M in Q1 2026.
- How has Catalyst Pharmaceutical's payment of liabilities arising from asset acquisition changed year-over-year?
- Catalyst Pharmaceutical's payment of liabilities arising from asset acquisition increased by 19.7% year-over-year, from $1.09M to $1.3M.
- What is the long-term trend for Catalyst Pharmaceutical's payment of liabilities arising from asset acquisition?
- Over 3 years (2022 to 2025), Catalyst Pharmaceutical's payment of liabilities arising from asset acquisition has grown at a 83.9% compound annual growth rate (CAGR), from $738K to $4.59M.
- What does payment of liabilities arising from asset acquisition mean?
- This represents the cash payment made to settle deferred obligations or contingent considerations resulting from prior asset or business acquisitions. It tracks the fulfillment of financial commitments made during the deal-making process. Investors monitor this to understand the long-term cash impact of past acquisition strategies on current liquidity.